1. Introduction {#sec1}
===============

In 2002, Gruberg and colleagues \[[@B1]\] coined the term "obesity paradox" to describe their counterintuitive finding that overweight and obese patients with coronary artery disease (CAD) had better outcomes than their normal-weight counterparts. Over the past decade, this unexpected finding has been observed in a range of cardiovascular disease (CVD) pathologies and in several patient groups without CVD \[[@B2]\], suggesting that the obesity paradox is less population specific than originally thought. For example, one recent report \[[@B3]\] found an obesity paradox in patients without CAD as determined by stress single photon emission computed tomography myocardial perfusion imaging. Additionally, two recent studies in patients with CAD \[[@B4], [@B5]\] found that cardiorespiratory fitness significantly alters the obesity paradox. However, the results of these studies may have been influenced by the presence of smoking and/or other health problems in the normal-weight reference groups.

In an attempt to better isolate the influence of fitness on the obesity paradox, we furthered our study of prospective data from our previous report in middle-aged men with known or suspected CAD who were referred for exercise testing as a part of an extensive medical workup \[[@B4]\]. Within the current study, a healthier cohort of individuals who participated in the Veterans Exercise Testing Study (VETS) were selected for further investigation in an attempt to determine what factors were contributory to mortality. The cohort selected included individuals who had never smoked, had no known baseline cardiopulmonary disease or diabetes, and had a normal exercise test. To avoid the confounding influence of age \[[@B6]\], we confined our investigation to men aged 40 to 65 years. Using 9-year follow-up data, we further explored the obesity paradox in middle-aged men with suspected CAD and assessed the extent to which cardiorespiratory fitness modifies the relation of adiposity to mortality in this population.

2. Materials and Methods {#sec2}
========================

2.1. Study Population {#sec2.1}
---------------------

The primary Veterans Exercise Testing Study (VETS) is a prospective epidemiologic investigation of veteran patients begun in 1987. All subjects were referred to exercise testing for either a routine evaluation or to evaluate for exercise-induced ischemia. Participants in the present study were drawn from a cohort of 7775 male veterans referred to one of two university-affiliated Veterans affairs medical centers (Long Beach, Ca, from 1987 to 1991; Palo Alto, Ca, from 1992 to 2003) with followup on all-cause mortality for at least 1 year. All subjects gave informed written consent for participation in the study and the institutional review boards at both sites approved the study. Additional information on study methods and subject characteristics of this cohort has been published elsewhere \[[@B7]\]. For this analysis, we excluded participants: (1) with missing data (*n* = 175); (2) with BMI \<18.5 kg/m^2^ (*n* = 51); (3) under 40 and over 65 years of age (*n* = 2528); (4) with documented CVD (defined as history of myocardial infarction, CAD documented via angiogram, abnormal exercise testing via a graded exercise test, coronary angioplasty, coronary bypass surgery, chronic heart failure, stroke, and/or peripheral vascular disease) (*n* = 2510); (5) with diabetes (*n* = 321); (6) who ever smoked (*n* = 1379). The current analysis included 811 participants ([Figure 1](#fig1){ref-type="fig"}).

2.2. Clinical Evaluation and Exercise Testing {#sec2.2}
---------------------------------------------

A standardized medical examination by a physician, including personal and family histories, was completed for all participants prior to exercise testing. All demographic, clinical, and medication information was obtained from patients\' computerized medical records just before the maximal exercise test. Each individual also was asked to verify the computerized information with regard to history of chronic disease, current medications, and cigarette smoking habits. Medications were not changed or stopped before the exercise test occurred.

Maximal exercise testing was performed using an individualized ramp protocol \[[@B8]\] on either a treadmill (*n* = 764) or an electromagnetically-braked cycle ergometer (*n* = 47). Before exercise testing, patients completed a Veterans Specific Activity Questionnaire (VSAQ) to estimate their exercise capacity, which allowed most patients to reach maximal exertion within the recommended range of 8 to 12 minutes \[[@B9]\]. In addition to completing the VSAQ, height and weight were measured immediately prior to the exercise test using standard procedures. From this data, body mass index (BMI) was calculated for each individual as weight in kilograms divided by the square of height in meters. Subjects were assigned to one of two categories according to BMI-defined obesity status: nonobese (18.5--29.9 kg/m^2^) and obese (≥30.0 kg/m^2^).

Prior to exercise testing, supine resting heart rate and blood pressure were assessed after 5 minutes. Blood pressure was recorded on alternate minutes throughout the test, and a 12-lead electrocardiogram was continuously monitored and printed every minute. A computerized system automatically increased workload after an individualized walking speed (treadmill) or watts (cycle) was established and predicted values for maximal exercise capacity were entered. Subjects were encouraged to exercise until volitional fatigue in the absence of symptoms or other indicators of ischemia. The patient\'s subjective level of exertion was assessed by the Borg 6--20 scale \[[@B10]\]. Standard clinical criteria for terminating the tests (e.g., fall in systolic blood pressure, ST-segment depression \>2.0 mm, dangerous arrhythmias) were followed \[[@B11]\], but no heart rate or time limit was imposed and a maximal effort was encouraged.

Cardiorespiratory fitness was calculated from final treadmill speed and grade or cycle ergometer watts as metabolic equivalents (METs) using standard American College of Sports Medicine equations (one MET is defined as the energy expended at rest, which is equivalent to an oxygen consumption of 3.5 mL·kg^−1^·min^−1^) \[[@B11]\]. A standardized method for categorizing fitness does not exist. However, in epidemiological studies, the lowest third for the population is frequently defined as "low fitness" \[[@B12]\]. Therefore, we grouped participants for analysis as "unfit" and "fit" according to the lower third and upper two-thirds of cardiorespiratory fitness for the population, respectively.

2.3. Mortality Surveillance {#sec2.3}
---------------------------

Participants were followed for at least 1 year from their baseline examination until their death or until 30 December, 2004. We recorded death dates from the Veterans Affairs Beneficiary Identification and Record Locator System File. The Social Security Death Index was used to match all subjects to their record according to Social Security number. Accuracy of deaths was reviewed by two clinicians blinded to exercise test results and confirmed using the Veterans Affairs computerized medical records.

2.4. Statistical Analysis {#sec2.4}
-------------------------

Number Crunching Statistical Software (Kaysville, UT) was used for all statistical analyses. The mean and SD of each variable were calculated with participants categorized as nonobese and obese. Cox proportional hazards analyses were used to assess separate and combined associations of cardiorespiratory fitness and adiposity at baseline with the risk of all-cause mortality. To test for the interactions of cardiorespiratory fitness, adiposity, and mortality, we calculated an interaction term for METs and BMI as continuous variables entered into an age-adjusted model. For stratified analyses, we selected nonobese and fit men as the reference group and calculated hazard ratios (HRs) of all-cause mortality for the remaining three fitness-obesity status groups (i.e., nonobese/unfit, obese/fit, and obese/unfit). Covariates included age (years), ethnicity (non-Hispanic White, African-American, Hispanic, Asian- Pacific Islander, or unknown), hypertension (yes or no), hypercholesterolemia (yes or no), family history of coronary artery disease (yes or no), and CVD medication use (yes or no for each medication listed in [Table 1](#tab1){ref-type="table"}). We used two tailed *t*-tests to compare means for continuous variables and Chi-square comparisons for categorical variables and regarded a *P* value of \<0.05 as statistically significant.

3. Results {#sec3}
==========

After a mean followup of 8.7 years (range, 1.2 to 17.6 years), 95 patients died, for an annual mortality rate of 1.3%. Obese men, who represented 37% of the cohort, were comparable to nonobese men in age and ethnic composition, but were nearly twice as likely to be classified as unfit, had a higher prevalence of hypertension (56% versus 32%) and hypercholesterolemia (45% versus 34%) and a higher use of four cardiovascular medications: beta-blockers (20% versus 10%), calcium antagonists (19% versus 10%), antihypertensives (23% versus 17%), and ACE inhibitors (13% versus 5%) ([Table 1](#tab1){ref-type="table"}). Neither mean follow-up duration nor crude mortality rate differed significantly by obesity status.

Multivariate proportional HRs (95% confidence intervals \[CI\]) for independent associations of cardiorespiratory fitness and adiposity measures with all-cause mortality are shown in [Table 2](#tab2){ref-type="table"}. In the fully adjusted model, HRs (95% CI) were 0.90 (0.84--0.96; *P* = 0.001) per MET increment and 0.98 (0.93--1.02; *P* = 0.25) per unit BMI (kg/m^2^) increment. The results for the categorical variables are also shown in [Table 2](#tab2){ref-type="table"}. Whereas unfit men (*n* = 270) were 2.3 times more likely to die (*P* \< 0.001) compared to the reference group of 541 fit men, obese men (*n* = 300) were no more likely to die (*P* = 0.72) compared to the reference group of 511 nonobese men.

Testing of the interaction model revealed a significant interaction between BMI and METs (*P* \< 0.001), thus we proceeded with the stratified analysis ([Figure 2](#fig2){ref-type="fig"}). Unadjusted HRs (95% CIs) from Kaplan-Meier analysis for nonobese/unfit, obese/fit, and obese/unfit were 2.99 (1.63--5.47), 1.03 (0.53--2.00), and 2.18 (1.17--4.08). Using the group of 382 nonobese/fit men as the reference, multivariate HRs (95% CI) were 2.19 (1.29--3.73) for 129 nonobese/unfit men and 1.86 (1.07--3.23) for 141 obese/unfit men. However, all-cause mortality risk for 159 obese/fit men did not differ significantly from the reference group (*P* = 0.85).

4. Discussion {#sec4}
=============

Overall, the results demonstrate that obese men were at no greater risk for 9 year all-cause mortality than nonobese men. This is the first study to confirm the presence of an obesity paradox in a population of healthier middle-aged men in the VETS cohort and extends previous observations of an obesity paradox in healthy older men in the VETS \[[@B13]\]. Though it is unlikely that a single variable could fully explain the obesity paradox phenomenon, we nevertheless demonstrated that cardiorespiratory fitness level altered the obesity paradox: unfit men were roughly twice as likely to die as fit men regardless of obesity status, and fit men who were obese survived as well as nonobese/fit men.

Some have suggested that the obesity paradox is due to poorer health \[[@B14]\] or the negative influence of smoking \[[@B15]\] in the reference group of normal-weight subjects. In this study, we attempted to avoid these problems by selecting a group of middle-aged men referred to exercise testing for clinical reasons but deemed apparently healthy on the basis of a normal exercise test, no prior history of cardiopulmonary disease or diabetes, and who never smoked. Furthermore, by including exercise test data in the analysis, we attempted to isolate the independent influence of cardiorespiratory fitness on the obesity paradox phenomenon.

Several theories have been advanced in an attempt to explain the obesity paradox, including the finding that in most studies the obese population is younger \[[@B16]\] and the observed protective effect may be limited to the relatively short follow-up period of most studies \[[@B17]\]. While these factors may explain the obesity paradox in many prospective studies, the subjects in our study were homogeneous with respect to age and were followed for mortality for nearly 9 years. Others have suggested that obese patients may receive better medical care sooner \[[@B18]\], a possibility that cannot be ruled out in the present study.

Another line of criticism regarding the obesity paradox focuses on the limitations of BMI as a measure of adiposity, arguing that higher BMI may simply mean greater muscle mass which in turn implies a more favorable health status \[[@B19]\]. However, Pearson correlations in the range of 0.7 to 0.8 between BMI and percentage body fat have been reported for both men and women \[[@B20], [@B21]\]. And a recent systematic review and meta-analysis of the diagnostic performance of BMI to identify obesity defined by body adiposity found that when BMI is ≥30 kg/m^2^, it is an excellent predictor of excess adiposity in both sexes \[[@B22]\]. The issue of BMI versus percentage body fat in obesity paradox was addressed by Lavie and colleagues \[[@B23]\] in a study of 209 heart failure patients, and in their more recent study of 529 patients with CAD \[[@B24]\]. Both studies found that both higher BMI and higher percentage body fat were independent predictors of better survival. And a recent study of 13,155 men with hypertension from the Aerobics Center Longitudinal Study (ACLS), found that CVD mortality risk was similar for BMI and percentage body fat \[[@B25]\]. Therefore, BMI appears to be an adequate marker of overall adiposity in population studies.

Few studies of obesity paradox include information on cardiorespiratory fitness \[[@B4], [@B5], [@B26]\], which greatly modifies mortality risk. For example, in our previous VETS report that included middle-aged male veterans with known or suspected CAD, an obesity paradox was present in the low-fitness group, but absent among participants registering high fitness. We did not observe such a dichotomy in the present study and the reason for this is likely due to the better health status of the reference group. However, veterans are a select group in that they have to meet military enlistment standards that include minimum fitness and maximum body weight criteria. Therefore, the results of the present study may be influenced by a "veteran effect" (i.e., all participants were previously fit and nonobese at the time of their enlistment).

Our study has several limitations: (1) since BMI was the only anthropometric measurement obtained, we were not able to evaluate body fat distribution characteristics; (2) all participants in this study were men who had prior military service and were referred to exercise testing for clinical reasons. Therefore, our results may not be generalized to civilians or women; (3) though our selection procedures enabled us to deem these subjects healthy, we cannot rule out the possibility that undetected CVD or other illnesses were present; (4) the extent of fitness improvement in adults, or the influence this may have on mortality, cannot be determined from the present investigation; (5) we did not have sufficient information about diet or physical activity patterns to study these factors; (6) since we only have baseline data on weight, exercise capacity, and other exposures, we do not know if changes in any of these variables occurred during followup and how this might have influenced the results; (7) data on peak VO~2~ were not available, which is the most accurate measure of cardiorespiratory fitness.

In conclusion, while our study suggests that the obesity paradox extends to healthier populations with only suspected CAD, cardiorespiratory fitness level rather than obesity accounted for differences in mortality risk. Whereas low fitness more than doubled all-cause mortality risk in this population, obesity provided neither protection against nor contributed to mortality. Thus, fitness predicted mortality independent of BMI. Our findings suggest that strategies to reduce mortality risk among obese adults should emphasize preserving or increasing cardiorespiratory fitness. Future studies should obtain simultaneous measures of fitness and adiposity and how *changes* in these parameters affect mortality and other health outcomes.
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![Multivariate hazard ratios for all-cause mortality by obesity status and fitness level. Each bar represents the relative risk after adjustment for age, ethnicity, hypertension, hypercholesterolemia, family history of coronary artery disease, and cardiovascular medication use with the relative risk of nonobese (BMI 18.5--29.9 kg/m^2^) and fit (\>9 METs) set at 1.0. Grey bars represent unfit (lowest third of distribution) and dark bars fit (upper two-thirds of distribution). Error bars represent 95% confidence intervals. Differed from reference: \**P* \< 0.05; \*\**P* \< 0.01.](JOBES2012-951582.002){#fig2}

###### 

Baseline characteristics of the study population.

  Characteristic                      BMI, 18.5--29.9 (*n* = 511)   BMI, ≥30.0 (*n* = 300)   *P*-value
  ----------------------------------- ----------------------------- ------------------------ -----------
  Age, years                          53.8 ± 7.5                    52.5 ± 6.7               0.01
  Non-Hispanic white, %               73.4                          66.3                     0.03
  Cardiorespiratory fitness, METs\*   11.2 ± 3.5                    9.2 ± 3.0                \<0.001
  Unfit, %\*                          25.2                          47.0                     \<0.001
  Fit, %\*                            74.8                          53.0                     
  Resting heart rate (bpm)            76.1 ± 14.1                   79.2 ± 14.7              0.003
  Resting blood pressure (mmHg)                                                              
   Systolic                           130.3 ± 18.2                  134.9 ± 18.7             \<0.001
   Diastolic                          83.9 ± 10.6                   86.4 ± 12.1              0.002
  Hypertension, %                     32.3                          56.3                     \<0.001
  Hypercholesterolemia, %             33.6                          44.9                     0.002
  Cardiovascular medication use, %                                                           
   Betablockers                       9.8                           20.0                     \<0.001
   Calcium antagonists                10.0                          19.0                     \<0.001
   Antihypertensives                  16.6                          23.3                     0.02
   Antiarrhythmics                    1.6                           1.3                      0.79
   ACE inhibitors                     4.7                           12.7                     \<0.001
   Anticoagulants                     9.4                           13.7                     0.06
   Statins                            4.3                           4.0                      0.83
   Diuretics                          1.0                           2.7                      0.06
  All-cause deaths, %                 11.9                          11.3                     0.80
  Followup, years                     8.9 ± 5.4                     8.3 ± 5.0                0.12

Data shown are mean ± SD unless otherwise specified. *P* values were calculated from the *t*-test for continuous variables and chi-square for categorical variables. BMI, body mass index; METs, metabolic equivalents.

\*1 MET = 3.5 mL/kg/min oxygen uptake, calculated from final treadmill speed and grade during maximal exercise test; lower third (\<9 METs) and upper two-thirds (≥9 METs) of cohort were classified as unfit and fit, respectively.

###### 

Independent associations of baseline fitness and BMI with all-cause mortality.

  Variables                  *n*   Deaths (%)   Model 1\*           Model 2^†^                       
  -------------------------- ----- ------------ ------------------- ------------ ------------------- ---------
  As continuous variables                                                                            
   Per MET                   811   95 (11.7)    0.91 (0.85--0.97)   0.002        0.90 (0.84--0.96)   0.001
   Per kg/m^2^               811   95 (11.7)    0.99 (0.96--1.09)   0.91         0.98 (0.93--1.02)   0.25
  As categorical variables                                                                           
   Fit                       541   45 (8.3)     1 (reference)                    1 (reference)       
   Unfit                     270   50 (18.5)    2.05 (1.34--3.15)   0.001        2.26 (1.43--3.56)   \<0.001
   Nonobese                  511   61 (11.9)    1 (reference)                    1 (reference)       
   Obese                     300   34 (11.3)    1.13 (0.72--1.76)   0.59         0.92 (0.58--1.46)   0.72

CI, confidence interval; HR, hazard ratio.

\*Adjusted for age, ethnicity, hypertension, hypercholesterolemia, family history of heart disease, and cardiovascular medication use.

^†^Adjusted for above plus METs (for BMI) and BMI (for METs) as continuous variables.
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